Bioresorbable vascular scaffold for the treatment of coronary in‐stent restenosis: New dawn or frost on snow?

Key Points BVS might be non‐inferiority compared to DES or DEB in ISR treatment in terms of 1‐year DOCE. BVS, especially thinner‐strut stent may be an attractive alternative in ISR setting. Large prospective randomized trials are needed to provide convince evidences to direct clinical practice in the future.